DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Acromegaly - Pipeline Review, H2 2016" report to their offering.
Acromegaly pipeline therapeutics constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by Companies and remaining by the Universities Institutes. The molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 3, 6 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Acromegaly - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Acromegaly Overview
- Therapeutics Development
- Pipeline Products for Acromegaly - Overview
- Pipeline Products for Acromegaly - Comparative Analysis
- Acromegaly - Therapeutics under Development by Companies
- Acromegaly - Therapeutics under Investigation by Universities/Institutes
- Acromegaly Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Acromegaly - Products under Development by Companies
- Acromegaly - Products under Investigation by Universities/Institutes
- Acromegaly - Companies Involved in Therapeutics Development
- Aegis Therapeutics, LLC
- Amryt Pharma plc
- Antisense Therapeutics Limited
- Chiasma, Inc.
- Crinetics Pharmaceuticals, Inc.
- DexTech Medical AB
- Foresee Pharmaceuticals, LLC
- Glide Pharmaceutical Technologies Limited
- Ionis Pharmaceuticals, Inc.
- Ipsen S.A.
- Italfarmaco S.p.A.
- Midatech Pharma Plc
- Novartis AG
- Peptron, Inc.
- Strongbridge Biopharma plc
- Sun Pharma Advanced Research Company Ltd.
For more information about this report visit http://www.researchandmarkets.com/research/4njdvz/acromegaly
